재발성 심막염 시장 보고서(2026년)

Recurrent pericarditis is a medical condition involving repeated inflammation episodes of the pericardium following an initial acute occurrence. It is commonly driven by immune mechanisms and is associated with recurring chest discomfort, increased inflammatory indicators, and potential fluid accumulation around the heart.

The key product types for recurrent pericarditis treatment include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine, biologics, and other therapies. NSAIDs are medications used to reduce inflammation, relieve pain, and manage symptoms associated with recurrent pericarditis. Diagnosis and assessment involve electrocardiography (ECG), echocardiography, and physical examination. Treatments are delivered via oral and injectable routes, and therapies are applied in colchicine, corticosteroid, and NSAID use cases. End users include hospitals, ambulatory surgical centers, clinics, home care settings, and emergency medical services (EMS).

Tariffs on specialty drugs, biologic agents, and diagnostic equipment are increasing treatment and monitoring costs in the recurrent pericarditis market. Import duties on biologic therapies and advanced imaging systems are impacting high value treatment segments the most. Regions that rely heavily on imported biologics, especially in emerging markets, are facing reimbursement and pricing pressure. Healthcare providers are adjusting procurement strategies and seeking regional suppliers. In some countries, tariffs are encouraging local production of generic anti inflammatory drugs. This is slightly improving affordability for standard therapies. It is also supporting domestic pharmaceutical manufacturers.

The recurrent pericarditis market research report is one of a series of new reports from The Business Research Company that provides recurrent pericarditis market statistics, including recurrent pericarditis industry global market size, regional shares, competitors with a recurrent pericarditis market share, detailed recurrent pericarditis market segments, market trends and opportunities, and any further data you may need to thrive in the recurrent pericarditis industry. This recurrent pericarditis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The recurrent pericarditis market size has grown rapidly in recent years. It will grow from $0.79 billion in 2025 to $0.88 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to historical reliance on NSAIDs and colchicine, rising diagnosis of inflammatory heart conditions, established cardiology care pathways, increased availability of echocardiography, guideline driven anti inflammatory therapy use.

The recurrent pericarditis market size is expected to see rapid growth in the next few years. It will grow to $1.32 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to growing adoption of biologic drugs, improved recurrence risk stratification, expansion of specialty cardiology clinics, higher awareness of immune mediated pericarditis, increasing use of targeted cytokine inhibitors. Major trends in the forecast period include higher use of targeted biologic therapies, expansion of long term disease monitoring, growth in anti inflammatory combination therapy, increased adoption of IL-1 inhibitors, structured recurrence prevention protocols.

The growing emphasis on precision medicine approaches is expected to drive the growth of the recurrent pericarditis market going forward. Precision medicine is a healthcare strategy that customizes prevention and treatment plans for individual patients based on their genetic makeup, environment, and lifestyle. The rising focus on precision medicine is fueled by improved treatment outcomes, as therapies tailored to an individual's genetic and biological profile enhance efficacy and reduce the risk of adverse effects. Recurrent pericarditis supports precision medicine by enabling targeted therapeutic approaches that focus on patient-specific inflammatory pathways, such as interleukin-1-mediated mechanisms, allowing for more personalized and effective disease management. For instance, in February 2025, according to NHS England, a UK-based public healthcare organization, in 2024 the NHS Genomic Medicine Service conducted over 810,000 genomic tests for patients across the life course in England, reflecting an 8% increase compared with 2023 and continuing year-on-year growth since the service was established. Therefore, the growing emphasis on precision medicine approaches is driving the growth of the recurrent pericarditis market.

Companies operating in the recurrent pericarditis market are focusing on developing anti-inflammatory and anti-fibrotic therapies to reduce pericardial inflammation, prevent long-term cardiac damage, improve patient quality of life, and minimize recurrence rates. Anti-inflammatory effects reduce inflammation in tissues, while anti-fibrotic effects prevent or reverse the formation of scar tissue, together helping to protect organs from damage and maintain normal function. For example, in October 2024, Cardiol Therapeutics Inc., a Canada-based clinical-stage life sciences company, advanced CardiolRx, a novel oral, non-immunosuppressive therapeutic for recurrent pericarditis that targets the NLRP3 inflammasome, a key upstream driver of IL-1-mediated inflammation. CardiolRx is being developed to prevent disease recurrence, particularly in patients who relapse after discontinuation of IL-1 blocker therapies such as rilonacept or anakinra. Through late-stage clinical programs, it aims to reduce pericarditis flares, alleviate chest pain, and normalize inflammatory markers (CRP).

In April 2024, Sanofi S.A., a France-based healthcare technology company, acquired Kiniksa Pharmaceuticals Limited for $2.5 billion. Through this acquisition, Sanofi aims to expand its portfolio in rare inflammatory and cardiovascular-related diseases, strengthen its immunology and inflammation capabilities, and accelerate growth through the addition of a late-stage and commercialized therapy in the recurrent pericarditis space. Kiniksa Pharmaceuticals Limited is a US-based healthcare technology company specializing in developing and commercializing targeted therapies for rare autoinflammatory and cardiovascular conditions, including monoclonal antibody treatments specifically approved for recurrent pericarditis.

Major companies operating in the recurrent pericarditis market are Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Lonza Group AG, Moderna Inc., and WuXi Biologics (Cayman) Inc.

North America was the largest region in the recurrent pericarditis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recurrent pericarditis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the recurrent pericarditis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The recurrent pericarditis market consists of revenues earned by entities by providing services such as cardiology consultations and clinical evaluations, diagnostic imaging and laboratory testing, monitoring of disease recurrence, patient follow-up and long-term care, and patient education and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The recurrent pericarditis market also includes sales of colchicine, immunosuppressive agents, disease-modifying anti-rheumatic drugs (DMARDs), analgesics, and adjunctive cardiovascular medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Recurrent Pericarditis Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses recurrent pericarditis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for recurrent pericarditis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The recurrent pericarditis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids; Colchicine; Biologics; Other Product Types
• 2) By Diagnosis And Assessment: Electrocardiography (ECG); Echocardiography; Physical Examination
• 3) By Route of Administration: Oral; Injectable
• 4) By Application: Colchicine Therapy; Corticosteroids; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 5) By End-User: Hospitals; Ambulatory Surgical Centers; Clinics; Home Care Settings; Emergency Medical Services (EMS)
• Subsegments:
• 1) By Non Steroidal Anti Inflammatory Drugs: Ibuprofen; Aspirin; Indomethacin; Naproxen
• 2) By Corticosteroids: Prednisone; Methylprednisolone; Hydrocortisone; Dexamethasone
• 3) By Colchicine: Oral Colchicine; Low Dose Colchicine; Extended Duration Colchicine Therapy
• 4) By Biologics: Interleukin One Inhibitors; Monoclonal Antibody Therapies; Targeted Cytokine Inhibitors
• 5) By Other Product Types: Immunosuppressive Agents; Analgesic Therapies; Supportive Combination Therapies
• Companies Mentioned: Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; Sanofi S.A.; Novartis AG; AstraZeneca PLC; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Eli Lilly and Company; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; Amgen Inc.; Gilead Sciences Inc.; Boehringer Ingelheim International GmbH; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Lonza Group AG; Moderna Inc.; and WuXi Biologics (Cayman) Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Recurrent Pericarditis Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Recurrent Pericarditis Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Recurrent Pericarditis Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Recurrent Pericarditis Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Immersive Technologies (Ar/Vr/Xr) & Digital Experiences
• 4.2. Major Trends
  • 4.2.1 Higher Use Of Targeted Biologic Therapies
  • 4.2.2 Expansion Of Long Term Disease Monitoring
  • 4.2.3 Growth In Anti Inflammatory Combination Therapy
  • 4.2.4 Increased Adoption Of Il-1 Inhibitors
  • 4.2.5 Structured Recurrence Prevention Protocols

5. Recurrent Pericarditis Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Cardiology Clinics
• 5.3 Ambulatory Surgical Centers
• 5.4 Specialty Heart Institutes
• 5.5 Emergency Care Centers

6. Recurrent Pericarditis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Recurrent Pericarditis Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Recurrent Pericarditis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Recurrent Pericarditis Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Recurrent Pericarditis Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Recurrent Pericarditis Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Recurrent Pericarditis Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Recurrent Pericarditis Market Segmentation

• 9.1. Global Recurrent Pericarditis Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Biologics, Other Product Types
• 9.2. Global Recurrent Pericarditis Market, Segmentation By Diagnosis And Assessment, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Electrocardiography (ECG), Echocardiography, Physical Examination
• 9.3. Global Recurrent Pericarditis Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable
• 9.4. Global Recurrent Pericarditis Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Colchicine Therapy, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• 9.5. Global Recurrent Pericarditis Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Ambulatory Surgical Centers, Clinics, Home Care Settings, Emergency Medical Services (EMS)
• 9.6. Global Recurrent Pericarditis Market, Sub-Segmentation Of Non Steroidal Anti Inflammatory Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ibuprofen, Aspirin, Indomethacin, Naproxen
• 9.7. Global Recurrent Pericarditis Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Prednisone, Methylprednisolone, Hydrocortisone, Dexamethasone
• 9.8. Global Recurrent Pericarditis Market, Sub-Segmentation Of Colchicine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Colchicine, Low Dose Colchicine, Extended Duration Colchicine Therapy
• 9.9. Global Recurrent Pericarditis Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Interleukin One Inhibitors, Monoclonal Antibody Therapies, Targeted Cytokine Inhibitors
• 9.10. Global Recurrent Pericarditis Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Immunosuppressive Agents, Analgesic Therapies, Supportive Combination Therapies

10. Recurrent Pericarditis Market Regional And Country Analysis

• 10.1. Global Recurrent Pericarditis Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Recurrent Pericarditis Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Recurrent Pericarditis Market

• 11.1. Asia-Pacific Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Recurrent Pericarditis Market

• 12.1. China Recurrent Pericarditis Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Recurrent Pericarditis Market

• 13.1. India Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Recurrent Pericarditis Market

• 14.1. Japan Recurrent Pericarditis Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Recurrent Pericarditis Market

• 15.1. Australia Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Recurrent Pericarditis Market

• 16.1. Indonesia Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Recurrent Pericarditis Market

• 17.1. South Korea Recurrent Pericarditis Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Recurrent Pericarditis Market

• 18.1. Taiwan Recurrent Pericarditis Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Recurrent Pericarditis Market

• 19.1. South East Asia Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Recurrent Pericarditis Market

• 20.1. Western Europe Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Recurrent Pericarditis Market

• 21.1. UK Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Recurrent Pericarditis Market

• 22.1. Germany Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Recurrent Pericarditis Market

• 23.1. France Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Recurrent Pericarditis Market

• 24.1. Italy Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Recurrent Pericarditis Market

• 25.1. Spain Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Recurrent Pericarditis Market

• 26.1. Eastern Europe Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Recurrent Pericarditis Market

• 27.1. Russia Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Recurrent Pericarditis Market

• 28.1. North America Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Recurrent Pericarditis Market

• 29.1. USA Recurrent Pericarditis Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Recurrent Pericarditis Market

• 30.1. Canada Recurrent Pericarditis Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Recurrent Pericarditis Market

• 31.1. South America Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Recurrent Pericarditis Market

• 32.1. Brazil Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Recurrent Pericarditis Market

• 33.1. Middle East Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Recurrent Pericarditis Market

• 34.1. Africa Recurrent Pericarditis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Recurrent Pericarditis Market, Segmentation By Product Type, Segmentation By Diagnosis And Assessment, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Recurrent Pericarditis Market Regulatory and Investment Landscape

36. Recurrent Pericarditis Market Competitive Landscape And Company Profiles

• 36.1. Recurrent Pericarditis Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Recurrent Pericarditis Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Recurrent Pericarditis Market Company Profiles
  • 36.3.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Recurrent Pericarditis Market Other Major And Innovative Companies

• Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Lonza Group AG, Moderna Inc.

38. Global Recurrent Pericarditis Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Recurrent Pericarditis Market

41. Recurrent Pericarditis Market High Potential Countries, Segments and Strategies

• 41.1 Recurrent Pericarditis Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Recurrent Pericarditis Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Recurrent Pericarditis Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer